Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ASND Ascendis Pharma A/S

Market Closed 11-13 16:00:00 EST

275.39

+8.32

+3.12%

盘后275.39

+0.000.00%

19:30 EST

High278.56	Low265.62	Vol826.10K
Open267.40	D1 Closing267.07	Amplitude4.85%
Mkt Cap18.23B	Tradable Cap18.05B	Total Shares66.19M
T/O227.28M	T/O Rate1.26%	Tradable Shares65.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ASND","market":"US","secType":"STK","nameCN":"Ascendis Pharma A/S","latestPrice":275.39,"timestamp":1794603600000,"preClose":267.07,"halted":0,"volume":826097,"hourTrading":{"tag":"盘后","latestPrice":275.39,"preClose":275.39,"latestTime":"19:30 EST","volume":14080,"amount":3877583.2175,"timestamp":1794616203206,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.031152881267083512,"floatShares":65539518,"shares":66189926,"eps":12.6,"marketStatus":"Market Closed","change":8.32,"latestTime":"11-13 16:00:00 EST","open":267.4,"high":278.56,"low":265.62,"amount":227275699.24739,"amplitude":0.048452,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":12.6,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":1422421200000,"exchange":"NASDAQ","adjPreClose":267.07,"preHourTrading":{"tag":"盘前","latestPrice":267.5,"preClose":267.07,"latestTime":"09:27 EST","volume":288,"amount":77101.20576,"timestamp":1794580060007,"change":0.43,"changeRate":0.00161,"amplitude":0.028083},"postHourTrading":{"tag":"盘后","latestPrice":275.39,"preClose":275.39,"latestTime":"19:30 EST","volume":14080,"amount":3877583.2175,"timestamp":1794616203206,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8651667177578426,"impliedVol":0.3241,"impliedVolPercentile":0.0518},"requestUrl":"/m/hq/s/ASND","defaultTab":"news","newsList":[{"id":"1122842605","title":"Movement Alert｜Ascendis Pharma A/S Intraday Rise 4.14% in Regular Trading, Price Target Increase and Q3 Results Beat Support Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1122842605","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122842605?lang=en_us&edition=fundamental","pubTime":"2026-11-14 02:11","pubTimestamp":1794593464,"startTime":"0","endTime":"0","summary":"On November 14, Ascendis Pharma A/S rose 4.14% in Regular Trading, trading at $278.14 per share, with turnover of $84.0114 million.The move appears supported by a fresh analyst price target increase...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Wedbush Lifts Ascendis Target to $346 After Q3 Beat","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683450247","title":"RBC Capital Remains a Buy on Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2683450247","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683450247?lang=en_us&edition=fundamental","pubTime":"2026-11-14 00:55","pubTimestamp":1794588942,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Luca Issi maintained a Buy rating on Ascendis Pharma yesterday and set a price target of $290.00. Issi covers the Healthcare se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","BK4207","BK4588","LU0029864427.USD","LU0889565916.HKD","LABU","LU1267930573.SGD","ASND","XLV","LU0708994859.HKD","GSIB","XBI","BK4139","LU0128525929.USD","BK4581","LU0109394709.USD","LU0310800379.SGD","MEDI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683084215","title":"Wedbush Raises Price Target on Ascendis Pharma to $346 From $327, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2683084215","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683084215?lang=en_us&edition=fundamental","pubTime":"2026-11-13 20:45","pubTimestamp":1794573954,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) has an average rating of buy and mean price target of $312.24, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","LU0320765992.SGD","BK4139","LU0109394709.USD","MEDI","BK4585","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683487508","title":"Ascendis Pharma Price Target Cut to $335.00/Share from $344.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2683487508","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683487508?lang=en_us&edition=fundamental","pubTime":"2026-11-13 20:45","pubTimestamp":1794573900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ASND","MEDI","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683152508","title":"Ascendis Pharma price target raised to $274 from $268 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2683152508","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683152508?lang=en_us&edition=fundamental","pubTime":"2026-11-13 20:35","pubTimestamp":1794573345,"startTime":"0","endTime":"0","summary":"Canaccord raised the firm’s price target on Ascendis Pharma (ASND) to $274 from $268 and keeps a Hold rating on the shares. The firm noted 3Q reven...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-price-target-raised-to-274-from-268-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-price-target-raised-to-274-from-268-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","ASND","LU0109394709.USD","LU0889565916.HKD","BK4139","BK4585","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683727265","title":"Why Did Ascendis Pharma (ASND) Shares Move Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2683727265","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683727265?lang=en_us&edition=fundamental","pubTime":"2026-11-13 19:27","pubTimestamp":1794569272,"startTime":"0","endTime":"0","summary":"MMitch LawlerNovember 13, 2026","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/why-did-ascendis-pharma-asnd-shares-move-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/why-did-ascendis-pharma-asnd-shares-move-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ASND","BK4585","MEDI","BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683572424","title":"Ascendis Pharma price target lowered to $335 from $344 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2683572424","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683572424?lang=en_us&edition=fundamental","pubTime":"2026-11-13 19:15","pubTimestamp":1794568546,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Ascendis Pharma (ASND) to $335 from $344 and keeps a Buy rating on the s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-price-target-lowered-to-335-from-344-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-price-target-lowered-to-335-from-344-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0889565916.HKD","LU0320765992.SGD","MEDI","LU0109394709.USD","BK4139","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683785565","title":"Ascendis Pharma a/S : TD Cowen Raises Target Price to $352 from $341","url":"https://stock-news.laohu8.com/highlight/detail?id=2683785565","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683785565?lang=en_us&edition=fundamental","pubTime":"2026-11-13 16:19","pubTimestamp":1794557949,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261113:nFWN46U0FN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDI","LU0109394709.USD","BK4585","LU0889565916.HKD","ASND","BK4139","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683517012","title":"Atrium Therapeutics Q3 Collaboration Revenue Rises on BMS Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2683517012","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683517012?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:18","pubTimestamp":1794518313,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics Q3 collaboration revenue rises on BMS milestoneOverviewUS biopharma's Q3 collaboration revenue rose, driven by BMS milestone paymentCompany posted Q3 net loss as R&D expenses incre","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL2N46T1HB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU0985481810.HKD","LU0109394709.USD","LU1430594728.SGD","LU1571399168.USD","LU1670711123.USD","LU0868494617.USD","LU2360032135.SGD","LU2596442595.SGD","LU0096364046.USD","LU0267386448.USD","IE00BJT1NW94.SGD","BK4588","LU1868836914.USD","LU2242646821.SGD","LU0320765992.SGD","MEDI","BK4534","IE0009355771.USD","LU1983299246.USD","LU0321505868.SGD","LU1868837136.USD","LU1883839398.USD","LU1323610961.USD","ANNX","ASND","BK4532","BMY","IHE","LU1868836757.USD","BK4007","FTXH","LU1670710588.SGD","BK4559","LQDA","LU0114720955.EUR","LU0225771236.USD","BK4585","LU0321505439.SGD","LU1718418525.SGD","LU0306807586.USD","LU0882574055.USD","LU2125154778.USD","BK4505","LU2125154935.USD","RNA","LU1670710661.SGD","LU1032466523.USD","LU0237698245.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683151548","title":"Ascendis Pharma A/S Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2683151548","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683151548?lang=en_us&edition=fundamental","pubTime":"2026-11-13 00:51","pubTimestamp":1794502264,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S reports results for the quarter ended September 30 - Earnings SummaryAscendis Pharma A/SASND.OQreported quarterly adjusted earnings of 1.08 per share for the quarter ended Septembe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL5N46T2E6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","BK4585","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","ASND","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682979596","title":"Ascendis Pharma Total Liabilities Fall to EUR 926.73 Million from EUR 1.47 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2682979596","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682979596?lang=en_us&edition=fundamental","pubTime":"2026-11-12 20:54","pubTimestamp":1794488091,"startTime":"0","endTime":"0","summary":"Ascendis Pharma Total Liabilities Fall to EUR 926.73 Million From EUR 1.47 BillionAscendis Pharma assets rose to EUR 2.43 billion at September 30, 2026, from EUR 1.3 billion at December 31, 2025.Total","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nNDLbxyCtB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","BK4139","LU0889565916.HKD","ASND","MEDI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682966075","title":"Ascendis Pharma Q3 Non-IFRS Earnings, Revenue Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2682966075","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682966075?lang=en_us&edition=fundamental","pubTime":"2026-11-12 20:51","pubTimestamp":1794487860,"startTime":"0","endTime":"0","summary":"Ascendis Pharma  reported Q3 non-IFRS earnings Thursday of 1.71 euros  per diluted share, up from 0.40 euros a year earlier.Total revenue for the quarter ended Sept. 30 was 369.7 million euros, up from 213.6 million euros a year earlier.Analysts surveyed by FactSet expected 361.4 million euros.Shares of Ascendis Pharma were up 1.8% in Thursday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","BK4139","MEDI","LU0109394709.USD","BK4585","LU0320765992.SGD","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682074595","title":"Ascendis Pharma Q3 Product Revenue Rises on Yorvipath Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2682074595","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682074595?lang=en_us&edition=fundamental","pubTime":"2026-11-12 20:44","pubTimestamp":1794487453,"startTime":"0","endTime":"0","summary":"Ascendis Pharma Q3 product revenue rises onYORVIPATH salesOverviewDenmark biopharma's Q3 product revenue rose 89% yr/yr, driven by YORVIPATH salesCompany posted Q3 net profit of 74 mln, reversing a lo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL2N46T0OJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","MEDI","LU0109394709.USD","BK4585","ASND","BK4139","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682959510","title":"Ascendis Pharma Q3 Adj. EPS $1.97 Beats $1.13 Estimate, Sales $425.432M Beat $417.230M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2682959510","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682959510?lang=en_us&edition=fundamental","pubTime":"2026-11-12 20:36","pubTimestamp":1794486978,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $1.97 per share which beat the analyst consensus estimate of $1.13 by 74.34 percent. This is a 328.26 percent increase over earnings of $0.46 per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/63180159/ascendis-pharma-q3-adj-eps-1-97-beats-1-13-estimate-sales-425-432m-beat-417-230m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","BK4585","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","ASND","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682595147","title":"Earnings Flash (ASND) Ascendis Pharma Posts Q3 Revenue 369.7M Euros, vs. FactSet Est of 361.4M Euros","url":"https://stock-news.laohu8.com/highlight/detail?id=2682595147","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682595147?lang=en_us&edition=fundamental","pubTime":"2026-11-12 20:35","pubTimestamp":1794486959,"startTime":"0","endTime":"0","summary":"Earnings Flash (ASND) Ascendis Pharma Posts Q3 Revenue 369.7M Euros, vs. FactSet Est of 361.4M Euros","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682595902","title":"Ascendis Pharma Q3 EPS EUR 1.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2682595902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682595902?lang=en_us&edition=fundamental","pubTime":"2026-11-12 20:35","pubTimestamp":1794486951,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nPLXB46LRC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","MEDI","ASND","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682955435","title":"Press Release: Ascendis Pharma Reports Third Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2682955435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682955435?lang=en_us&edition=fundamental","pubTime":"2026-11-12 20:30","pubTimestamp":1794486600,"startTime":"0","endTime":"0","summary":"-- Q3 2026 product revenue of EUR366 million , comprising EUR291. million for YORVIPATH, EUR59 million for SKYTROFA, and EUR16. -- Received positive CHMP and COMP opinions recommending EU marketing. -- Final EC decision for TransCon CNP expected in Q4 2026; first EU launch. -- Presented Week 52 sentinel cohort data in infants with achondroplasia. aged 0 to <2 years showing TransCon CNP stabilized or improved foramen. magnum stenosis, and increased linear growth; topline pivotal data. -- YORVIPATH revenue for the third quarter of 2026 totaled EUR291. quarters. Outside the U.S., new patient demand accelerated through. new commercial launches. YORVIPATH is now available commercially. or through named patient programs in more than 40 countries.-- Presented data from pooled analysis of Phase 2 PaTH Forward and. Phase 3 PaTHway trials at ASN 2026 demonstrating sustained,clinically meaningful improvements in kidney function in adults. -- Results from the Phase 3 PaTHway China and PaTHway Japa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","LU0109394709.USD","032820.KR","BK4139","BK9077","BK4022","LU0320765992.SGD","LU0889565916.HKD","BK7095","MEDI","R","SGA","SGA.AU","BK4125","BK4585","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682315153","title":"Ascendis Pharma A/S Expected to Post Earnings of 94 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2682315153","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682315153?lang=en_us&edition=fundamental","pubTime":"2026-11-10 22:11","pubTimestamp":1794319868,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S <ASND.OQ> expected to post earnings of94cents a share - Earnings PreviewAscendis Pharma A/SASND.OQASND.Ois expected to  show a rise in quarterly revenue when it reports  results on","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261110:nL5N46R1MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","BK4139","LU0320765992.SGD","ASND","LU0109394709.USD","LU0889565916.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681867912","title":"Ascendis Pharma's TransCon CNP Gets EU Orphan-Drug Designation Recommendation for Achondroplasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2681867912","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681867912?lang=en_us&edition=fundamental","pubTime":"2026-11-06 22:29","pubTimestamp":1793975355,"startTime":"0","endTime":"0","summary":"Ascendis Pharma  said Friday that the European Medicines Agency's Committee for Orphan Medicinal Products recommended maintaining orphan medicinal product designation for once-weekly TransCon CNP for the treatment of achondroplasia in children.If TransCon CNP receives marketing authorization in the European Union, the orphan designation would provide 10 years of market exclusivity, the biopharmaceutical company said.The European Commission's final decision on Ascendis' marketing authorization application is expected in the fourth quarter.The recommendation follows a positive opinion from the EMA's Committee for Medicinal Products for Human Use on marketing authorization for once-weekly TransCon CNP to treat children aged 2 years and older with achondroplasia whose epiphyses are not closed.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU0320765992.SGD","LU0889565916.HKD","ASND","MEDI","EPV","LU0109394709.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681692728","title":"Ascendis Pharma Plans Yuviwel Launch in Germany in Q1 2027, Pending EU Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2681692728","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681692728?lang=en_us&edition=fundamental","pubTime":"2026-11-06 21:01","pubTimestamp":1793970117,"startTime":"0","endTime":"0","summary":"Ascendis Pharma Plans YUVIWEL Launch in Germany in Q1 2027, Pending EU ApprovalAscendis Pharma plans its first EU launch of TransCon CNP as YUVIWEL in Germany in Q1 2027, subject to European Commissio","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261106:nNDLc8x3QL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BN0W2V16.EUR","LU0889565916.HKD","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","LU2095319765.USD","BCDF","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","BK4585","LU0314104364.USD","NDAQ","LU0109394709.USD","BK4588","SG9999014013.SGD","IE00BN0W2T93.GBP","LU2210149790.SGD","SG9999014021.USD","IE00BKPKM429.USD","BK4112","SG9999014039.USD","SG9999014005.SGD","BK4139","IE00BGHQF748.EUR","MEDI","ASND"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascendispharma.com","stockEarnings":[{"period":"1week","weight":0.0723},{"period":"1month","weight":0.2132},{"period":"3month","weight":0.1082},{"period":"6month","weight":0.1451},{"period":"1year","weight":0.3339},{"period":"ytd","weight":0.2915}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":-0.0198},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0206},{"period":"1year","weight":0.1225},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.031281},{"month":2,"riseRate":0.583333,"avgChangeRate":0.050705},{"month":3,"riseRate":0.416667,"avgChangeRate":0.030446},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.031037},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.005122},{"month":6,"riseRate":0.666667,"avgChangeRate":0.035016},{"month":7,"riseRate":0.583333,"avgChangeRate":-0.006819},{"month":8,"riseRate":0.75,"avgChangeRate":0.084399},{"month":9,"riseRate":0.583333,"avgChangeRate":0.025323},{"month":10,"riseRate":0.5,"avgChangeRate":-0.000419},{"month":11,"riseRate":0.833333,"avgChangeRate":0.051415},{"month":12,"riseRate":0.545455,"avgChangeRate":0.041981}],"exchange":"NASDAQ","name":"Ascendis Pharma A/S","nameEN":"Ascendis Pharma A/S","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ascendis Pharma A/S,ASND,Ascendis Pharma A/S股票,Ascendis Pharma A/S股票老虎,Ascendis Pharma A/S股票老虎国际,Ascendis Pharma A/S行情,Ascendis Pharma A/S股票行情,Ascendis Pharma A/S股价,Ascendis Pharma A/S股市,Ascendis Pharma A/S股票价格,Ascendis Pharma A/S股票交易,Ascendis Pharma A/S股票购买,Ascendis Pharma A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction